Response and survival outcomes in the MDS/CMML cohort
MDS/CMML
DISEASE
Among 8 patients with MDS/CMML, 1 patient (13%) achieved CR, 4 patients (50%) achieved mCR (2 of whom also achieved HI), and 1 patient (13%) achieved HI, for an overall response rate of 75%. One patient with low blast percentage at start (4%) received 6 cycles and achieved stable disease at best response. One patient withdrew consent on day 5 and opted for supportive care and therefore was unevaluable for response.The median number of cycles received in the MDS/CMML cohort is 5 (range 1–16 cycles). The median follow-up is 17.6 months (range 1.0–19.3 months). No patients proceeded to subsequent allogeneic SCT. As of the data cutoff, 4 of the 5 responding patients have relapsed and 6 patients have died. One patient with complex cytogenetics with a 